Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

  • Smith, Brandon B.A.
  • Engel, Priya M.P.H.
  • Wu, Jashin J. M.D.

  • 1Drexel University College of Medicine, Philadelphia, PA

    2California University of Science and Medicine, Colton, CA

    3University of Miami Miller School of Medicine, Miami, FL [email protected]

Dr. Wu reports receiving grants from AbbVie, Amgen, Eli Lilly, Incyte, Janssen, Novartis, and Pfizer; consulting fees from AbbVie, Almirall, Amgen, Arcutis Biotherapeutics, Aristea Therapeutics, Bausch Health, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Codex Labs, Dermavant Sciences, DermTech, Dr. Reddy's Laboratories, Eli Lilly, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health; and speaker's fees from AbbVie, Amgen, Bausch Health, EPI Health, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, and UCB. No other potential conflict of interest relevant to this letter was reported.

New England Journal of Medicine 388(24):p 2299, June 15, 2023. | DOI: 10.1056/NEJMc2304782

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

  • Silverberg, Jonathan I. M.D., Ph.D., M.P.H
  • Guttman-Yassky, Emma M.D., Ph.D.
  • Thaçi, Diamant M.D.
  • Irvine, Alan D. M.D.
  • Stein Gold, Linda M.D.
  • Blauvelt, Andrew M.D.
  • Simpson, Eric L. M.D.
  • Chu, Chia-Yu M.D., Ph.D.
  • Liu, Zhuqing Ph.D.
  • Gontijo Lima, Renata M.D.
  • Pillai, Sreekumar G. Ph.D.
  • Seneschal, Julien M.D., Ph.D.
New England Journal of Medicine Publish Ahead of Print, March 18, 2023. | DOI: 10.1056/NEJMoa2206714
Copyright © 2023 Massachusetts Medical Society. All rights reserved.